Genentech announce positive results from phase 3 IMbrave050 study

pharmafile | January 19, 2023 | News story | Research and Development  

Genentech, based in California, US, has announced positive results from its phase 3 IMbrave050 trial, after the study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis.


IMbrave050 is investigating the safety and efficacy Tecentriq® (atezolizumab) plus Avastin® (bevacizumab) in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survival. Is it a global, multicentre, open-label, randomised study of 662 people, with a ratio of 1:1 to receive either Tecentriq® (1,200 mg every three weeks) plus Avastin® (15 mg/kg every three weeks) for a maximum of 12 months, or no intervention with active surveillance.


This combination showed a statistically significant improvement in RFS in the intention-to-treat population of HCC patients who have an increased risk of recurrence following resection or ablation with curative intent, compared with active surveillance.


“Today, more than 70% of people with early-stage HCC may have their cancer return after surgery, which is associated with poorer prognosis and shorter survival. IMbrave050 is the first phase 3 study to show that a cancer immunotherapy combination reduced the risk of disease returning in people with this type of HCC. We are excited by the clinical benefit that this adjuvant Tecentriq combination may bring to people with early liver cancer and look forward to seeing more mature data to further confirm the benefit,” said Levi Garraway, MD, PhD, chief medical officer and head of Global Product Development.


James Spargo

Related Content

No items found

Latest content